MedTrace Logo

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

NCT00275665 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-12-19

No results posted yet for this study

Summary

This study is being done in stem cell transplant recipients to see if taking the drug valganciclovir can prevent or reduce serious cytomegalovirus (CMV) infections that can occur 100 days or later after transplant.

Conditions

  • Bone Marrow Stem Cell Transplant

Interventions

DRUG

Valganciclovir

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fred Hutchinson Cancer Center

    collaborator OTHER

  • City of Hope National Medical Center

    collaborator OTHER

  • University of Florida

    collaborator OTHER

  • University of Michigan

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Mark R. Litzow, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00275665 on ClinicalTrials.gov